Asked by: Brian Mathew (Liberal Democrat - Melksham and Devizes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to prioritise (a) lung and (b) respiratory health in the NHS Long Term Plan.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The 10-Year Health Plan will deliver the three big shifts the National Health Service needs to be fit for the future: from hospital to community, from analogue to digital, and from sickness to prevention. All of these are relevant to improving respiratory health in all parts of the county.
More tests and scans delivered in the community, better joint working between services, and greater use of apps and wearable technology will all help people manage their long-term conditions, including respiratory conditions, closer to home. Earlier diagnosis of conditions will help people manage their conditions, prevent deterioration and improve survival rates.
Asked by: Brian Mathew (Liberal Democrat - Melksham and Devizes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the availability of ear wax removals in primary care settings in Melksham and Devizes constituency.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Integrated care boards (ICBs) have a statutory responsibility to commission cost-effective healthcare to meet the needs of their local population. This includes the arrangement of services for ear wax removal. When ICBs exercise their functions, including commissioning healthcare services such as ear wax removal, they have a duty to reduce inequalities between persons with respect to their ability to access health services, and to reduce inequalities between patients with respect to the outcomes achieved for them by the provision of health services.
Manual ear syringing is no longer advised by the National Institute for Health and Care Excellence (NICE) due to the risks associated with it, such as trauma to their ear drum or infection, so general practitioners (GPs) will often recommend home treatment remedies to alleviate ear wax build-up.
However, in line with the NICE’s guidance, a person may require ear wax removal treatment if the build-up of earwax is linked with hearing loss. A GP could then consider referring the patient into audiology services, which ICBs are responsible for commissioning.
Asked by: Brian Mathew (Liberal Democrat - Melksham and Devizes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to further research into rare diseases.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funds rare disease research through the National Institute for Health and Care Research (NIHR). 17 NIHR Biomedical Research Centres support research into rare diseases and the NIHR is working in partnership with the Medical Research Council to co-fund a UK Rare Disease Research Platform which brings together research teams across the United Kingdom with patients, stakeholders and technologies to deliver rare disease research with greater impact.
Asked by: Brian Mathew (Liberal Democrat - Melksham and Devizes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department will allow UK oncologists to test for genetic weaknesses by carrying out Whole Genomic Sequencing.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Genomic testing in the National Health Service in England is provided through the NHS Genomic Medicine Service and delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory, which includes tests for over 7,000 rare diseases and over 200 clinical indications of cancer. Testing can be delivered using a range of technologies, including whole genome sequencing (WGS) or Next Generation Sequencing technology, large cancer gene panels, to ensure that a patient receives the most appropriate genomic testing depending on their individual circumstances.
The National Genomic Test Directory sets out the eligibility criteria for patients to access testing as well as the genomic targets to be tested and the method that should be used. For most cancers, the National Genomic Test Directory outlines that large gene panels inclusive of targets for treatments should be offered as the first line option. WGS can then be offered to any cancer patient that requires it to determine their next stage of treatment.
Asked by: Brian Mathew (Liberal Democrat - Melksham and Devizes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential of targeted mutation treatments through genetic treatment for rare cancers.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Improvements in genomic capabilities have accelerated the development of new precision medicines which can target genomic mutations, including for rare cancers. To help make precision medicines available to patients, the National Health Service has supported access to clinical trials, where the eligibility is based on genomic variants. They also support the adoption and spread of innovative medicines through an innovative genomic testing service and commercial medicines framework.
In October 2022, NHS England published the first NHS Genomics Strategy, Accelerating Genomic Medicine in the NHS, which outlines the vision for embedding genomics in the NHS over the next five years. The strategy includes a commitment to work with partners, including the National Institute for Health and Care Excellence and the Medicines and Healthcare products Regulatory Agency, to identify and prepare for the rapid introduction of companion diagnostic genomic testing. This is critical to ensuring easy access to innovative precision medicines and technologies. Further information on Accelerating Genomic Medicine in the NHS is available at the following link:
Additionally, the National Cancer Plan will include further details on how we will improve outcomes for cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, including genetic treatments.
Asked by: Brian Mathew (Liberal Democrat - Melksham and Devizes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) improve child and adolescent mental health services and (b) increase the speed of diagnosis for (i) ADHD and (ii) autism.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Too many children and young people are not receiving the mental health care they need, and we know that waits for mental health services are far too long. We are determined to change that. We will recruit 8,500 additional mental health workers across children and adult services to reduce delays and provide faster treatment. We will also provide access to a specialist mental health professional in every school in England and introduce open access Young Futures hubs in every community.
It is the responsibility of integrated care boards (ICBs) to make available appropriate provision to meet the health and care needs of their local population, including autism and attention deficit hyperactivity disorder (ADHD) services, in line with relevant National Institute for Health and Care Excellence guidelines.
In April 2023, NHS England published a national framework and operational guidance to help ICBs and the National Health Service to deliver improved outcomes for children, young people and adults referred to an autism assessment service. In 2024/25, £4.3 million is available nationally to improve services for autistic children and young people, including autism assessment services.
We are supporting a taskforce that NHS England has established to look at ADHD service provision and its impact on patient experience. The taskforce is bringing together expertise from across a broad range of sectors, including the NHS, education and justice, to better understand the challenges affecting people with ADHD including timely access to services and support.
In conjunction with the taskforce, NHS England is carrying out detailed work to develop a data improvement plan, understand the provider and commissioning landscape and capture examples from ICBs who are trialling innovative ways of delivering ADHD services.
Asked by: Brian Mathew (Liberal Democrat - Melksham and Devizes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to tackle shortages of ADHD medication.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The resilience of the United Kingdom’s supply chains is a key priority, and we are committed to helping build long term supply chain resilience for medicines. The Department works in partnership with industry, the National Health Service, and the wider health system to help ensure the continuity of the supply of medical products, including for attention deficit hyperactivity disorder (ADHD) medicines. These issues are often global in nature. We monitor and manage medicine supply issues at a national level, so that stocks remain available to meet regional and local demand, and therefore there are no specific measures for the West Midlands.
As a result of intensive work, some issues with ADHD medicines have been resolved. All strengths of lisdexamfetamine, atomoxetine capsules, atomoxetine oral solution, and guanfacine prolonged-release tablets are now available.
However, whilst the supply of methylphenidate prolonged-release tablets has improved, issues still persist. We are continuing to work to resolve these remaining issues by engaging with all suppliers of methylphenidate prolonged-release tablets to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support the continued growth in demand for the short and long-term. The Department is also working with new suppliers of methylphenidate prolonged-release tablets to improve supply and resiliency for the UK market.
We are supporting an ADHD taskforce that NHS England has established to examine ADHD service provision. The taskforce will bring together expertise from across a broad range of sectors, including the NHS, education, and justice, to help provide a joined-up approach in response to concerns around rising demand. In collaboration with NHS England’s national ADHD data improvement plan, we plan to combine modelling for future growth forecasts, which will be shared with industry to improve demand forecasting for ADHD medicines.
The Department has worked with NHS specialists to develop advice on prescribing alternative ADHD medications. We expect that ADHD service providers should follow this guidance and offer rapid responses for urgent advice, especially for high-risk patients. To aid decision-making at the point of the prescribing and dispensing of ADHD medicines, we continue to update a list of available ADHD products on the Specialist Pharmacy Service website.